UY27031A1 - Uso de agonistas selectivos del receptor de dopamina d4 para tratar disfunción sexual - Google Patents

Uso de agonistas selectivos del receptor de dopamina d4 para tratar disfunción sexual

Info

Publication number
UY27031A1
UY27031A1 UY27031A UY27031A UY27031A1 UY 27031 A1 UY27031 A1 UY 27031A1 UY 27031 A UY27031 A UY 27031A UY 27031 A UY27031 A UY 27031A UY 27031 A1 UY27031 A1 UY 27031A1
Authority
UY
Uruguay
Prior art keywords
dopamine
sexual dysfunction
selective agonists
receptor selective
treat sexual
Prior art date
Application number
UY27031A
Other languages
English (en)
Inventor
Jorge D Brioni
Diane L Donnelly-Roberts
Teodozyj Kolasa
Gin C Hsieh
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27109879&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY27031(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US09/985,974 external-priority patent/US20020103105A1/en
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of UY27031A1 publication Critical patent/UY27031A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Abstract

Uso de agonistas selectivos del receptor de dopamina D4 y composiciones que contienen agonistas selectivos del receptor de dopamina D4 para el tratamiento de la disfunción sexual.
UY27031A 2000-11-22 2001-11-21 Uso de agonistas selectivos del receptor de dopamina d4 para tratar disfunción sexual UY27031A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71831100A 2000-11-22 2000-11-22
US09/985,974 US20020103105A1 (en) 2000-11-22 2001-11-07 Use of selective dopamine D4 receptor agonists for treating sexual dysfunction

Publications (1)

Publication Number Publication Date
UY27031A1 true UY27031A1 (es) 2002-07-31

Family

ID=27109879

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27031A UY27031A1 (es) 2000-11-22 2001-11-21 Uso de agonistas selectivos del receptor de dopamina d4 para tratar disfunción sexual

Country Status (25)

Country Link
EP (1) EP1345608B1 (es)
JP (1) JP2004534725A (es)
KR (1) KR20030051857A (es)
CN (1) CN1531434A (es)
AR (1) AR035600A1 (es)
AT (1) ATE358483T1 (es)
AU (2) AU2002226895B2 (es)
BG (1) BG107810A (es)
BR (1) BR0110450A (es)
CA (1) CA2429383A1 (es)
CZ (1) CZ20031458A3 (es)
DE (1) DE60127712T2 (es)
ES (1) ES2284727T3 (es)
HK (1) HK1059884A1 (es)
HU (1) HUP0402358A3 (es)
IL (1) IL155094A0 (es)
MX (1) MXPA03004547A (es)
NO (1) NO20032304L (es)
NZ (1) NZ525086A (es)
PE (1) PE20020557A1 (es)
PL (1) PL365890A1 (es)
SK (1) SK7242003A3 (es)
TW (1) TWI293254B (es)
UY (1) UY27031A1 (es)
WO (1) WO2002041894A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
EP1509213A2 (en) * 2002-05-23 2005-03-02 Abbott Laboratories Acetamides and benzamides that are useful in treating sexual dysfunction
JP2009503020A (ja) 2005-08-03 2009-01-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 肥満症の治療におけるフリバンセリンの使用
EP1945214A1 (en) 2005-10-29 2008-07-23 Boehringer Ingelheim International GmbH Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
DE602007004615D1 (de) 2006-06-30 2010-03-18 Boehringer Ingelheim Pharma Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
CA2660476C (en) 2006-08-14 2015-11-17 Boehringer Ingelheim International Gmbh Formulations of flibanserin and method for manufacturing the same
CA2661613C (en) 2006-08-25 2016-01-26 Boehringer Ingelheim International Gmbh Controlled release system and method for manufacturing the same
PE20091188A1 (es) 2007-09-12 2009-08-31 Boehringer Ingelheim Int Compuesto 1-[2-(4-(3-trifluorometil-fenil)piperazin-1-il)etil]-2,3-dihidro-1h-benzimidazol-2-ona (flibanserina), sus sales de adicion y composiciones farmaceuticas que los contienen
EP3581567A1 (en) * 2011-04-10 2019-12-18 Atir Holding S.A. Heterocyclic compounds and uses thereof in the treatment of sexual disorders
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0775118B1 (en) * 1994-08-05 2003-06-04 Pfizer Inc. Benzimidazole derivatives having dopaminergic activity
US5945117A (en) * 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction
EP0982030A3 (en) * 1998-08-17 2000-05-10 Pfizer Products Inc. 2,7-substituted octahydro-pyrrolo 1,2-a]pyrazine derivatives as 5ht 1a ligands
US6291471B1 (en) * 1998-12-17 2001-09-18 Abb Holdings, Inc. Use of apomorphine for the treatment of organic erectile dysfunction in males

Also Published As

Publication number Publication date
CA2429383A1 (en) 2002-05-30
AR035600A1 (es) 2004-06-16
NZ525086A (en) 2006-07-28
HUP0402358A2 (hu) 2005-03-29
DE60127712T2 (de) 2007-12-27
NO20032304D0 (no) 2003-05-21
HK1059884A1 (en) 2004-07-23
MXPA03004547A (es) 2004-03-26
EP1345608B1 (en) 2007-04-04
WO2002041894A2 (en) 2002-05-30
DE60127712D1 (de) 2007-05-16
CN1531434A (zh) 2004-09-22
KR20030051857A (ko) 2003-06-25
CZ20031458A3 (cs) 2004-02-18
WO2002041894A3 (en) 2002-10-17
HUP0402358A3 (en) 2009-08-28
IL155094A0 (en) 2003-10-31
EP1345608A2 (en) 2003-09-24
BG107810A (bg) 2004-02-27
TWI293254B (en) 2008-02-11
NO20032304L (no) 2003-07-15
PE20020557A1 (es) 2002-06-25
ES2284727T3 (es) 2007-11-16
ATE358483T1 (de) 2007-04-15
BR0110450A (pt) 2005-02-09
PL365890A1 (en) 2005-01-10
JP2004534725A (ja) 2004-11-18
AU2002226895B2 (en) 2006-10-12
SK7242003A3 (en) 2004-01-08
AU2689502A (en) 2002-06-03

Similar Documents

Publication Publication Date Title
UY28150A1 (es) Agentes terapeuticos
AR052774A1 (es) Inmunoterapia para trastornos autoinmunes
AR055123A1 (es) Asociacion de un agente hipnotico de duracion de accion larga y un agente hipnotico de duracion de accion larga y un agente hipnotico de duracion de accion corta, composicion farmaceutica que la contiene y su aplicacin en terapeutica
CL2009001874A1 (es) Uso de bacillus subtilis qst713 nrrl b-21661 para formular una composición probiótica para un animal; y composición probiotica de bacillus subtilis qst713 nrrl b-21661.
ECSP034656A (es) Derivados benzimidazol y piridilimidazol como ligandos para gabaa
ECSP055609A (es) "Uso de inhibidores de la IkB-quinasa para el tratamiento del dolor"
PA8468401A1 (es) Compuestos para el tratamiento de la isquemia
PA8596901A1 (es) Inhibidores de p38 y metodos de uso de ellos
CL2008001268A1 (es) Compuestos derivados de n-[6-amino-5-aril-piridin-2-il]-carboxamida; composicion farmaceutica que los comprende; composicion farmaceutica combinada que los comprende junto a otro agente farmacologico adicional; y uso de los mismos en el tratamiento del dolor.
UY27188A1 (es) Uso de agonistas inversos de gabaa en combinación con agonistas parciales del receptor de nicotina, estrógenos, moduladores selectivos de estrógenos o vitamina e, para el tratamiento de trastornos cognitivos.
PA8502901A1 (es) Tratamiento de combinacion con il-1ra y compuestos que inhiben el procesamiento y la liberacion de il-1
UY27031A1 (es) Uso de agonistas selectivos del receptor de dopamina d4 para tratar disfunción sexual
UY27894A1 (es) Derivados de cinamida.
UY27203A1 (es) Bencimidazoles útiles en el tratamiento de la disfunción sexual
UY28925A1 (es) Nuevos derivados de aminopiridina y su uso como fármacos
NO20052557D0 (no) Morfolinderivater for bruk som dopamin-agonister i behandling av blant annet seksuell dysfunksjon.
PA8555501A1 (es) Compuestos de benzimidazol sustituido y su uso para el tratamiento del cancer
PA8618401A1 (es) Prevencion y tratamiento de enfermedades cardiacas hipertensivas mediante el uso de los estrogenos selectivos 8beta-vinil-estra-1,3,5(10)-trien-3,17beta-diol y 17beta-fluor-9alfa-vinil-estra-1.3,5(10)-trien-3,16alfa-diol
BR0215064A (pt) Agonistas receptores seletivos de dopamina d3 para o tratamento de disfunção sexual
AR019327A1 (es) Combinacion de fentolamina y apomorfina para el tratamiento de la funcion y disfuncion sexual humana
ECSP034612A (es) Uso de agonista selectivos del receptor de dopamina d4 para tratar la disfuncion sexual
UY28918A1 (es) Nuevos derivados de indazol e indolona y su uso como productos farmacéuticos
ECSP034752A (es) Benzimidazoles utiles en el tratamiento de la dinfuncion sexual
UY27706A1 (es) Bencimidazoles útiles en el tratamiento de la disfunción sexual.
AR047550A1 (es) Tratamiento de la depresion y otros trastornos afectivos

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20141105